<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02640547</url>
  </required_header>
  <id_info>
    <org_study_id>P15-767</org_study_id>
    <secondary_id>PLHCVRWE01</secondary_id>
    <nct_id>NCT02640547</nct_id>
  </id_info>
  <brief_title>Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C</brief_title>
  <official_title>Real World Evidence (RWE) of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Poland (HCV RWE PMOS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IST GmbH, Germany</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to provide evidence of the effectiveness and obtain patient reported
      outcomes (PRO) and work productivity data of the interferon-free regimen of Paritaprevir
      (PTV)/ritonavir (r) + Ombitasvir (OBV), +/- Dasabuvir (DSV), +/- Ribavirin in chronic
      hepatitis C virus infected participants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Sustained Virological Response 12 Weeks Post-treatment (SVR12)</measure>
    <time_frame>12 weeks after the last dose of study drug</time_frame>
    <description>Sustained virologic response is defined as hepatitis C virus ribonucleic acid (HCV RNA) levels less than the lower limit of quantification 12 weeks after the last dose of study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the Usage Pattern of the Treatment Regimen</measure>
    <time_frame>Up to end of treatment, maximum week 24</time_frame>
    <description>Case report form collection to evaluate the usage pattern of treatment regimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of the Direct Acting Antiviral (DAA) Dose taken in Relation to the Target Dose of DAA</measure>
    <time_frame>Up to end of treatment, maximum week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of the Ribavirin (RBV) dose taken in relation to the target dose of RBV</measure>
    <time_frame>Up to end of treatment, maximum week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Missed RBV Treatment Days in Relation to the Target Number of RBV Treatment Days</measure>
    <time_frame>Up to end of treatment, maximum week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Co-morbidities</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Concomitant Medications</measure>
    <time_frame>Day 0 to end of treatment, maximum week 24</time_frame>
    <description>Concomitant medication used from the time when the decision to made to initiate treatment with the PTV/r+OBV+/-DSV+/-RBV until after the last dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Participants Quality of Life measured with the EuroQol 5 Dimension 5 Level (EQ-5D-5L) Questionnaire</measure>
    <time_frame>Day 0 to post treatment Week 24</time_frame>
    <description>Five items in the EQ-5D-5L questionnaire (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) are rated on 5 levels of severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Participants Workability Measured with the Work Productivity and Activity Impairment (WPAI):Hepatitis C Questionnaire</measure>
    <time_frame>Day 0 to post treatment week 24</time_frame>
    <description>Questionnaire measures work time missed, work and non-work activity impairment due to a specified health problem during the past seven days.</description>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Actual">394</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Genotype 1 (GT1) participants treated without Ribavirin (W12)</arm_group_label>
    <description>GT1 participants receiving PTV/r+OBV+DSV for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotype 1 (GT1) participants treated with Ribavirin (W12)</arm_group_label>
    <description>GT1 participants receiving PTV/r+OBV+DSV+RBV for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotype 1 (GT1) participants treated with Ribavirin (W24)</arm_group_label>
    <description>GT1 participants receiving PTV/r+OBV+DSV+RBV for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotype 4 (GT4) participants treated with Ribavirin (W12)</arm_group_label>
    <description>GT4 participants receiving PTV/r+OBV+RBV for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotype 4 (GT4) participants treated with Ribavirin (W24)</arm_group_label>
    <description>GT4 participants receiving PTV/r+OBV+RBV for 24 weeks.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Chronic Hepatitis C (CHC)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Treatment-naïve or -experienced adult male or female patients with confirmed CHC,
             genotype 1 or 4, receiving combination therapy with the interferon-free ABBVIE REGIMEN
             ± RBV according to standard of care and in line with the current local label.

          -  If RBV is co-administered with the ABBVIE REGIMEN, it has been prescribed in line with
             the current local label (with special attention to contraception requirements and
             contraindication during pregnancy).

          -  Patients must voluntarily sign and date a patient authorization to use and/or disclose
             his/her anonymized health data prior to inclusion into the study.

          -  Patient must not be participating or intending to participate in a concurrent
             interventional therapeutic trial

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Flisiak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uniwersytecki Szpital Kliniczny w Bialymstoku</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny w Bialymstoku /ID# 148335</name>
      <address>
        <city>Bialystok</city>
        <zip>15540</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Obserwacyjno-Zakazny im. T. Browicza /ID# 151251</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-030</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Specjalistyczny w Chorzowie /ID# 148337</name>
      <address>
        <city>Chorzow</city>
        <zip>47400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zespol Zakladow Opieki Zdrowotnej w Cieszynie /ID# 148388</name>
      <address>
        <city>Cieszyn</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Specjalistyczny im. N.M.P. w Czestochowie /ID# 148386</name>
      <address>
        <city>Czestochowa</city>
        <zip>42200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ All-Medicus /ID# 148385</name>
      <address>
        <city>Katowice</city>
        <zip>40660</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Wojewodzki w Koszalinie im. Mikolaja Kopernika /ID# 148390</name>
      <address>
        <city>Koszalin</city>
        <zip>75581</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPZOZ Krakowie Szpital Specjalistyczny im. Jana Pawla II /ID# 148333</name>
      <address>
        <city>Krakow</city>
        <zip>31-202</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Specjalistyczny Szpital im Dr Wl. Bieganskiego /ID# 151245</name>
      <address>
        <city>Lodz</city>
        <zip>91-347</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ID Clinic /ID# 151244</name>
      <address>
        <city>Myslowice</city>
        <zip>41-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Wojewodzki w Opolu /ID# 151246</name>
      <address>
        <city>Opole</city>
        <zip>45-372</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specjalistyczny Szpital im. dr Alfreda Sokolowskiego /ID# 148392</name>
      <address>
        <city>Walbrzych</city>
        <zip>58300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MED-FIX Centrum Medyczne Sp. z o.o. /ID# 151248</name>
      <address>
        <city>Warsaw</city>
        <zip>53-522</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Specjalistyczny im J. Gromkowskiego we /ID# 151249</name>
      <address>
        <city>Wroclaw</city>
        <zip>51149</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Specjalistyczny im J. Gromkowskiego we /ID# 151250</name>
      <address>
        <city>Wroclaw</city>
        <zip>51149</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ - Lubuska Secjalistyczna Poradnia Chorob Wątroby Sp. z /ID# 148396</name>
      <address>
        <city>Zielona Gora</city>
        <zip>65044</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Przychodnia Specjalistyczna &quot;Gemini&quot; /ID# 151247</name>
      <address>
        <city>Zychlin</city>
        <zip>62571</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2015</study_first_submitted>
  <study_first_submitted_qc>December 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2015</study_first_posted>
  <last_update_submitted>April 3, 2017</last_update_submitted>
  <last_update_submitted_qc>April 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fibrosis</keyword>
  <keyword>Chronic Hepatitis C</keyword>
  <keyword>Cirrhosis</keyword>
  <keyword>Work Ability</keyword>
  <keyword>Dasabuvir</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>Observational Study</keyword>
  <keyword>Paritaprevir/r/Ombitasvir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>March 6, 2018</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>March 21, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

